Balancing transparency and confidentiality

1. Introduction

Balancing transparency and confidentiality is an important principle of modern legal governance, particularly in biotechnology, pharmaceutical research, scientific innovation, healthcare administration, and intellectual property protection. Transparency ensures that decisions, research activities, regulatory approvals, and institutional practices remain open to appropriate scrutiny. Confidentiality, on the other hand, protects sensitive personal information, commercial secrets, research data, and legally privileged communications from unauthorised disclosure.

In biotechnology, this balance becomes particularly important because research institutions, pharmaceutical companies, genetic laboratories, and regulatory authorities frequently handle sensitive information. Such information may include genetic sequences, clinical trial results, patient medical records, unpublished research findings, manufacturing processes, and commercially valuable inventions.

Excessive secrecy can weaken public trust, prevent accountability, and conceal regulatory violations. Similarly, unrestricted disclosure can compromise individual privacy, intellectual property rights, research integrity, and commercial interests.

Therefore, legal systems must establish appropriate mechanisms that promote institutional transparency while protecting information that genuinely requires confidentiality.

2. Meaning and Importance of Transparency and Confidentiality

Transparency refers to the availability of relevant information concerning institutional decisions, regulatory procedures, research activities, financial arrangements, and legal compliance. It allows individuals, stakeholders, and regulatory authorities to examine whether organisations are performing their responsibilities lawfully.

Confidentiality refers to the legal and ethical obligation to protect sensitive information against unauthorised access, disclosure, use, or distribution.

Both principles serve important purposes in biotechnology governance.

The major objectives include:

Promoting accountability among research institutions and biotechnology companies.

Protecting personal and genetic information.

Preventing misuse of confidential scientific data.

Maintaining public confidence in biomedical research.

Protecting legitimate commercial and intellectual property interests.

Ensuring transparency in regulatory approvals and clinical trials.

Supporting ethical research and responsible information management.

3. Legal Framework Governing Transparency and Confidentiality in India

A. Right to Information Act, 2005

The Right to Information Act promotes transparency and accountability in public authorities.

Section 4 requires public authorities to maintain and proactively disclose specified categories of information.

However, Section 8 provides exemptions from disclosure in certain circumstances.

Important provisions include:

Section 8(1)(d): Protects commercial confidence, trade secrets, and intellectual property where disclosure would harm the competitive position of a third party, subject to the statutory public-interest qualification.

Section 8(1)(e): Protects information available to a person in a fiduciary relationship, subject to the public-interest override.

Section 8(1)(j): Addresses disclosure of personal information, subject to the current statutory wording and applicable amendments.

Section 11: Establishes the procedure for consultation with third parties in relevant cases.

These provisions demonstrate that transparency must be balanced against legitimate confidentiality interests.

B. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act establishes a legal framework for processing digital personal data.

It is relevant to biotechnology institutions because genetic research may involve personal information relating to identifiable individuals.

Research organisations must consider applicable requirements concerning lawful processing, notices, security safeguards, and individual rights.

The Act also provides for specified legitimate uses and exemptions, subject to their statutory conditions.

C. Information Technology Act, 2000

Section 72 of the Information Technology Act addresses punishment for breach of confidentiality and privacy by persons who obtain access to electronic records, books, registers, correspondence, information, documents, or other material under powers conferred by the Act.

Section 72A addresses disclosure of information in breach of a lawful contract in specified circumstances.

These provisions are relevant to the protection of electronic research records and confidential information.

D. Patents Act, 1970

The Patents Act protects qualifying inventions through patent rights.

Patent applications involve disclosure of technical information to the public in exchange for statutory protection.

This arrangement reflects an important relationship between transparency and confidentiality: inventors must disclose their inventions sufficiently to satisfy patent requirements, while trade secrets may remain confidential when they are not publicly disclosed.

E. Indian Council of Medical Research Guidelines

The ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017, establish important principles concerning informed consent, privacy, confidentiality, and ethical research practices.

These guidelines are particularly relevant to genetic research, clinical trials, genomic databases, and medical investigations involving human participants.

4. Application in Biotechnology and Pharmaceutical Research

A. Genetic Information and Patient Privacy

Genetic information can reveal sensitive details about an individual's biological characteristics and potential health risks. It may also reveal information relevant to biological relatives.

Research institutions must therefore establish appropriate confidentiality safeguards when collecting, storing, analysing, and sharing genetic information.

At the same time, transparency is necessary regarding research objectives, consent procedures, data usage, and potential risks.

B. Clinical Trial Transparency

Clinical trials involve human participants and require appropriate regulatory and ethical supervision.

Information concerning trial registration, research methodology, safety monitoring, and trial outcomes is important for public accountability.

However, participants' identities, personal medical records, and other confidential information must remain protected.

C. Commercial Research and Trade Secrets

Biotechnology companies frequently invest substantial resources in developing pharmaceutical formulations, laboratory technologies, genetic engineering methods, and manufacturing processes.

Such information may constitute commercially valuable confidential information.

Organisations may protect legitimate trade secrets through confidentiality agreements, restricted access, internal policies, and appropriate security measures.

However, confidentiality should not be used to conceal unlawful activities, serious safety violations, or information that must legally be disclosed.

D. Regulatory Transparency

Regulatory authorities must provide appropriate information concerning licensing decisions, environmental approvals, clinical trial permissions, and compliance procedures.

Public disclosure promotes accountability and allows affected communities to understand decisions that may influence their health and environment.

Nevertheless, authorities must protect confidential personal information and legitimate commercial interests in accordance with applicable law.

5. Important Case Laws

1. Justice K.S. Puttaswamy v. Union of India (2017)

The Supreme Court of India recognised privacy as a fundamental right under Article 21 and other freedoms guaranteed by Part III of the Constitution.

The judgment established that informational privacy is an important element of individual autonomy and dignity.

The Court also recognised that privacy is not absolute and that restrictions must satisfy constitutional requirements.

Relevance: This judgment is particularly important in biotechnology because genetic information, medical records, and genomic databases contain sensitive personal information. Research institutions must balance transparency with the constitutional protection of individual privacy.

2. Central Public Information Officer, Supreme Court of India v. Subhash Chandra Agarwal (2019)

The Supreme Court examined the relationship between transparency under the Right to Information Act and confidentiality interests, including privacy and fiduciary relationships.

The Court recognised that transparency and privacy must be balanced by applying the relevant statutory provisions and considering the public interest.

Relevance: The judgment provides guidance for biotechnology regulatory authorities when deciding whether institutional records, research information, or confidential documents should be disclosed under the RTI framework.

3. Girish Ramchandra Deshpande v. Central Information Commissioner (2012)

The Supreme Court considered the disclosure of personal information under the Right to Information Act.

It held that personal information relating to public servants cannot automatically be disclosed merely because an RTI application has been filed. The applicable statutory exemptions and public-interest considerations must be examined.

Relevance: The case is relevant to biotechnology institutions because employee records, researchers' personal details, medical information, and confidential professional documents may require protection from unnecessary disclosure.

4. R. Rajagopal v. State of Tamil Nadu (1994)

The Supreme Court examined the relationship between freedom of expression and the right to privacy.

The Court recognised that individuals have privacy rights concerning matters relating to their private lives, subject to recognised legal limitations.

Relevance: This decision is significant for biotechnology and medical research because publishing research findings involving identifiable individuals may raise privacy concerns. Researchers must ensure that disclosure of personal information is legally justified and appropriately authorised.

5. Zee Telefilms Ltd. v. Union of India (2005)

The Supreme Court examined the scope of the expression "State" under Article 12 of the Constitution in relation to the Board of Control for Cricket in India.

The judgment discussed the legal distinction between public authorities and private bodies performing significant functions.

Relevance: The decision is useful when examining transparency obligations across biotechnology institutions. Different legal obligations may apply to government research organisations, statutory regulators, and private biotechnology companies depending on their legal status and the applicable legislation.

6. Mechanisms for Balancing Transparency and Confidentiality

Biotechnology institutions should adopt structured information governance policies to protect both principles.

Important mechanisms include:

1. Informed consent: Research participants should receive appropriate information about the collection, use, storage, and sharing of their biological and personal data.

2. Controlled information access: Sensitive research records should be accessible only to authorised individuals.

3. Data anonymisation: Identifying information should be removed or appropriately protected when research information is shared for legitimate purposes.

4. Confidentiality agreements: Employees, researchers, consultants, and collaborators should follow appropriate confidentiality obligations.

5. Public disclosure policies: Institutions should publish relevant regulatory approvals, research objectives, safety information, and legally required reports.

6. Independent ethical oversight: Institutional ethics committees should review confidentiality and disclosure practices in relevant biomedical research.

7. Information security audits: Regular assessments should identify weaknesses in research databases and confidential information management systems.

7. Challenges in Maintaining the Balance

Maintaining transparency and confidentiality creates several legal and practical challenges.

First, public accountability versus commercial interests: Biotechnology companies may resist disclosure of commercially valuable research information, even when public-interest considerations justify greater transparency.

Second, genetic privacy: Genetic information may reveal sensitive information about individuals and their relatives, making disclosure particularly complicated.

Third, international research collaboration: Biotechnology research frequently involves institutions across different countries, each having different privacy and disclosure requirements.

Fourth, regulatory secrecy: Excessive confidentiality within regulatory institutions may reduce public confidence and make it difficult to assess the safety of scientific developments.

Fifth, technological risks: Unauthorised access, data breaches, and improper sharing of digital research records can compromise confidentiality.

These challenges require clear legal standards, effective institutional policies, independent supervision, and proportionate disclosure procedures.

8. Conclusion

Balancing transparency and confidentiality is essential for responsible biotechnology governance. Transparency promotes public accountability, scientific credibility, and regulatory integrity, while confidentiality protects personal privacy, genetic information, research participants, and legitimate commercial interests.

The decisions in Justice K.S. Puttaswamy v. Union of India (2017), CPIO, Supreme Court of India v. Subhash Chandra Agarwal (2019), and R. Rajagopal v. State of Tamil Nadu (1994) provide important judicial guidance on privacy, information disclosure, and individual autonomy.

Ultimately, biotechnology institutions must adopt a balanced approach that ensures legally required disclosure without unnecessarily exposing confidential information. Effective information governance, informed consent, data protection, independent ethical review, and regulatory accountability are essential for maintaining public trust while encouraging scientific innovation.